Ebola virus (EV) causes hemorrhagic fever in humans and non-human primates. Among emerging infectious diseases, EV stands out for its impressive lethality. Acute mortality due to the Zaire strain of EV has been approximately 80% in human outbreaks. There is currently no therapy. ? The molecular pathogenesis of EVHF remains poorly understood. Recent studies have suggested that massive apoptosis of lymphocytes, along with dysregulated production of IFN-a, plays an important role in the pathogenesis of EVHF: ? (1) Survivors and fatalities have similar viral loads at the onset of illness. In fatalities, widespread lymphocyte apoptosis occurs prior to the development of an adequate adaptive (B and T cell mediated) immune response. In survivors, the adaptive immune response, arising in the absence of such pathological lymphocyte apoptosis, leads to viral clearance and disease resolution. Such large- scale lymphocyte apoptosis, associated with profound lymphopenia and destruction of lymphoid tissue, is recapitulated in macaque models of EVHF. The mechanism(s) underlying such apoptosis remains unclear. It is not due to direct viral infection; EV does not infect lymphocytes. ? (2) EVHF is associated with sustained high expression of IFN-a. In vitro infection of monocytes, cells that form a primary site of EV replication in vivo, also induces high levels of IFN-a secretion. In addition to driving the activation of NK cytolytic pathways (notable, given circumstantial evidence for granzyme B-mediated cytolytic pathways in EVHF-related lymphocyte apoptosis), IFN-a can directly induce lymphocyte apoptosis, through caspase-dependent and -independent mechanisms. ? The interrelated hypotheses underlying the proposed studies are that pathological apoptosis of lymphocytes and dysregulated production of IFN-a are integral to the pathogenesis of EVHF. The studies in this application will examine these hypotheses at multiple levels, ranging from the molecular to in vivo in the rhesus macaque model of EVHF . ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21AI053539-02
Application #
6650375
Study Section
Special Emphasis Panel (ZAI1-GPJ-M (M3))
Program Officer
Repik, Patricia M
Project Start
2002-09-01
Project End
2005-08-31
Budget Start
2003-09-01
Budget End
2005-08-31
Support Year
2
Fiscal Year
2003
Total Cost
$222,000
Indirect Cost
Name
Cincinnati Children's Hospital Medical Center
Department
Type
DUNS #
071284913
City
Cincinnati
State
OH
Country
United States
Zip Code
45229
Smith, Lauren M; Hensley, Lisa E; Geisbert, Thomas W et al. (2013) Interferon-? therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever. J Infect Dis 208:310-8
Hensley, Lisa E; Fritz, Lisa E; Jahrling, Peter B et al. (2004) Interferon-beta 1a and SARS coronavirus replication. Emerg Infect Dis 10:317-9